Eupraxia Pharmaceuticals (EPRX) Competitors $3.89 -0.04 (-1.02%) As of 10:17 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. MNMD, BCYC, VECT, DNTH, MRVI, RLAY, KURA, AUTL, CGEM, and SANAShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Mind Medicine (MindMed) (MNMD), Bicycle Therapeutics (BCYC), VectivBio (VECT), Dianthus Therapeutics (DNTH), Maravai LifeSciences (MRVI), Relay Therapeutics (RLAY), Kura Oncology (KURA), Autolus Therapeutics (AUTL), Cullinan Therapeutics (CGEM), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors Mind Medicine (MindMed) Bicycle Therapeutics VectivBio Dianthus Therapeutics Maravai LifeSciences Relay Therapeutics Kura Oncology Autolus Therapeutics Cullinan Therapeutics Sana Biotechnology Mind Medicine (MindMed) (NASDAQ:MNMD) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership. Does the media prefer MNMD or EPRX? In the previous week, Mind Medicine (MindMed) had 5 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 9 mentions for Mind Medicine (MindMed) and 4 mentions for Eupraxia Pharmaceuticals. Mind Medicine (MindMed)'s average media sentiment score of 1.38 beat Eupraxia Pharmaceuticals' score of 0.70 indicating that Mind Medicine (MindMed) is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mind Medicine (MindMed) 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, MNMD or EPRX? Mind Medicine (MindMed) has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Is MNMD or EPRX more profitable? Mind Medicine (MindMed)'s return on equity of -47.56% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mind Medicine (MindMed)N/A -47.56% -35.55% Eupraxia Pharmaceuticals N/A -219.64%-96.00% Does the MarketBeat Community believe in MNMD or EPRX? Mind Medicine (MindMed) received 53 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 91.94% of users gave Mind Medicine (MindMed) an outperform vote. CompanyUnderperformOutperformMind Medicine (MindMed)Outperform Votes5791.94% Underperform Votes58.06%Eupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo Votes Do insiders & institutionals have more ownership in MNMD or EPRX? 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 2.5% of Mind Medicine (MindMed) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate MNMD or EPRX? Mind Medicine (MindMed) presently has a consensus price target of $25.50, indicating a potential upside of 246.47%. Eupraxia Pharmaceuticals has a consensus price target of $10.50, indicating a potential upside of 169.92%. Given Mind Medicine (MindMed)'s higher probable upside, equities research analysts plainly believe Mind Medicine (MindMed) is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.27Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has higher earnings and valuation, MNMD or EPRX? Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMind Medicine (MindMed)N/AN/A-$95.73M-$1.29-5.71Eupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-5.12 SummaryMind Medicine (MindMed) beats Eupraxia Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.45M$6.92B$5.60B$8.61BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-5.408.8427.2219.97Price / SalesN/A255.17408.95152.58Price / CashN/A65.8538.2534.64Price / Book129.676.587.114.68Net Income-$28.22M$144.20M$3.24B$248.05M7 Day Performance-1.27%3.32%2.47%2.40%1 Month Performance0.91%10.53%8.66%6.14%1 Year Performance43.54%3.63%31.22%13.62% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.2979 of 5 stars$3.89-1.0%$10.50+169.9%+38.9%$139.45MN/A-5.4029MNMDMind Medicine (MindMed)1.9839 of 5 stars$7.69+2.8%$25.11+226.5%-1.7%$581.00MN/A-3.4040News CoveragePositive NewsAnalyst RevisionBCYCBicycle Therapeutics3.3664 of 5 stars$8.30-2.9%$25.00+201.2%-63.1%$574.81M$25.72M-2.52240News CoverageAnalyst RevisionVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeDNTHDianthus Therapeutics1.4349 of 5 stars$17.59+0.3%$53.00+201.3%-24.4%$565.69M$6.52M-7.0480Positive NewsAnalyst RevisionMRVIMaravai LifeSciences4.0533 of 5 stars$2.22+4.2%$6.64+199.0%-71.9%$565.35M$241.86M-1.35610Options VolumeRLAYRelay Therapeutics2.411 of 5 stars$3.29+3.5%$17.67+437.0%-53.8%$564.05M$7.68M-1.26330KURAKura Oncology4.4521 of 5 stars$6.42+1.9%$24.50+281.6%-67.8%$555.81M$67.99M-2.72130Analyst RevisionAUTLAutolus Therapeutics2.6306 of 5 stars$2.07+8.4%$9.32+350.2%-48.0%$550.91M$9.01M-1.71330High Trading VolumeCGEMCullinan Therapeutics1.6968 of 5 stars$8.96+2.4%$32.00+257.1%-61.4%$528.77MN/A-3.1530Analyst ForecastSANASana Biotechnology2.4885 of 5 stars$2.34+6.4%$10.80+361.5%-60.8%$527.62MN/A-1.67380Positive News Related Companies and Tools Related Companies Mind Medicine (MindMed) Competitors Bicycle Therapeutics Competitors VectivBio Competitors Dianthus Therapeutics Competitors Maravai LifeSciences Competitors Relay Therapeutics Competitors Kura Oncology Competitors Autolus Therapeutics Competitors Cullinan Therapeutics Competitors Sana Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EPRX Stock Free EPRX Stock Alerts